Payment overview · 2025
General Payments
$2,285.39
128 reported records · 27 companies
Healthcare provider profile · identity verified
Gary L Bohay, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TUCSON, AZ · NPI 1679534887
Verified facts
What the public records show
CMS Open Payments records show Gary L Bohay, M.D. received $2,285.39 in general payments during 2025 across 128 reported records.
GlaxoSmithKline, LLC. accounted for 13.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 44 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Prolia, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $309.96 | 13.6% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $202.51 | 8.9% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $197.26 | 8.6% | 14 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $187.30 | 8.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $166.59 | 7.3% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $160.68 | 7.0% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $153.65 | 6.7% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $130.79 | 5.7% | 6 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $107.85 | 4.7% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $89.21 | 3.9% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $79.84 | 3.5% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $54.70 | 2.4% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $54.19 | 2.4% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $45.16 | 2.0% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $45.14 | 2.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.48 | 1.9% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $40.40 | 1.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $37.06 | 1.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.02 | 1.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $26.86 | 1.2% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $19.19 | 0.8% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.02 | 0.8% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $18.67 | 0.8% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $17.33 | 0.8% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $16.86 | 0.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.45 | 0.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.22 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,285.39 | 128 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $197.55 | 11 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $187.30 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $166.59 | 13 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $128.57 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $119.96 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $113.27 | 6 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $112.41 | 7 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $107.85 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $103.51 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $102.42 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $96.45 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $89.21 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $82.60 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $81.76 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $79.84 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $68.69 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $68.69 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $68.69 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $68.47 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $57.17 | 5 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $54.19 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $54.19 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $46.81 | 4 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $45.16 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $45.14 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $40.40 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $37.06 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.34 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.34 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.69 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $29.02 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $26.86 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| Epclusa Normalized: epclusa |
Drug | Gilead Sciences, Inc. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $3.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 193 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 144 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 78 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 34 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 93 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
126 | 38 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
34 | 22 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
48 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
144 | 38 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
93 | 22 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
89 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
144 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
193 | 52 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
68 | 68 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1324 | 418 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1054 | 317 |
| Amlodipine Besylate | Amlodipine Besylate | 992 | 304 |
| Losartan Potassium | Losartan Potassium | 760 | 256 |
| Lisinopril | Lisinopril | 618 | 193 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 575 | 187 |
| Omeprazole | Omeprazole | 524 | 165 |
| Gabapentin | Gabapentin | 509 | 125 |
| Trazodone Hcl | Trazodone Hcl | 469 | 131 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 390 | 116 |
| Tamsulosin Hcl | Tamsulosin Hcl | 385 | 124 |
| Escitalopram Oxalate | Escitalopram Oxalate | 369 | 113 |
| Metoprolol Succinate | Metoprolol Succinate | 330 | 115 |
| Pravastatin Sodium | Pravastatin Sodium | 328 | 99 |
| Simvastatin | Simvastatin | 319 | 98 |
| Metformin Hcl | Metformin Hcl | 308 | 98 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 271 | 94 |
| Duloxetine Hcl | Duloxetine Hcl | 261 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 258 | 89 |
| Zolpidem Tartrate | Zolpidem Tartrate | 258 | 54 |
| Sertraline Hcl | Sertraline Hcl | 249 | 80 |
| Alprazolam | Alprazolam | 240 | 66 |
| Furosemide | Furosemide | 227 | 85 |
| Montelukast Sodium | Montelukast Sodium | 226 | 73 |
| Allopurinol | Allopurinol | 215 | 67 |
| Alendronate Sodium | Alendronate Sodium | 214 | 76 |
| Lorazepam | Lorazepam | 198 | 49 |
| Finasteride | Finasteride | 196 | 58 |
| Eliquis | Apixaban | 193 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 189 | 67 |
| Potassium Chloride | Potassium Chloride | 187 | 62 |
| Ezetimibe | Ezetimibe | 184 | 62 |
| Azithromycin | Azithromycin | 167 | 136 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 167 | 30 |
| Famotidine | Famotidine | 162 | 56 |
| Metformin Hcl Er | Metformin Hcl | 155 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 151 | 46 |
| Fluoxetine Hcl | Fluoxetine Hcl | 144 | 42 |
| Jardiance | Empagliflozin | 144 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 60 |
| Mirtazapine | Mirtazapine | 130 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 126 | 30 |
| Synthroid | Levothyroxine Sodium | 126 | 38 |
| Atenolol | Atenolol | 125 | 33 |
| Tramadol Hcl | Tramadol Hcl | 124 | 38 |
| Meloxicam | Meloxicam | 123 | 38 |
| Irbesartan | Irbesartan | 115 | 34 |
| Telmisartan | Telmisartan | 113 | 42 |
| Estradiol | Estradiol | 107 | 39 |
| Propranolol Hcl | Propranolol Hcl | 106 | 28 |
| Acyclovir | Acyclovir | 104 | 33 |
| Donepezil Hcl | Donepezil Hcl | 103 | 33 |
| Nebivolol Hcl | Nebivolol Hcl | 98 | 34 |
| Prednisone | Prednisone | 96 | 73 |
| Pregabalin | Pregabalin | 96 | 25 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 95 | 68 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 93 | 22 |
| Bupropion Xl | Bupropion Hcl | 90 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 89 | 31 |
| Xarelto | Rivaroxaban | 89 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 88 | 17 |
| Glipizide | Glipizide | 87 | 28 |
| Sumatriptan Succinate | Sumatriptan Succinate | 87 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 85 | 31 |
| Clonazepam | Clonazepam | 84 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 84 | 25 |
| Celecoxib | Celecoxib | 81 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 26 |
| Ipratropium Bromide | Ipratropium Bromide | 80 | 30 |
| Ozempic | Semaglutide | 78 | 20 |
| Carvedilol | Carvedilol | 77 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 26 |
| Azelastine Hcl | Azelastine Hcl | 73 | 31 |
| Buspirone Hcl | Buspirone Hcl | 73 | 22 |
| Glimepiride | Glimepiride | 73 | 24 |
| Paxlovid | Nirmatrelvir/Ritonavir | 68 | 68 |
| Paroxetine Hcl | Paroxetine Hcl | 65 | 18 |
| Terazosin Hcl | Terazosin Hcl | 65 | 24 |
| Diazepam | Diazepam | 62 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 60 | 13 |
| Rizatriptan | Rizatriptan Benzoate | 60 | 12 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 60 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 15 |
| Temazepam | Temazepam | 59 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 54 | 18 |
| Chlorthalidone | Chlorthalidone | 52 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 20 |
| Valacyclovir | Valacyclovir Hcl | 51 | 23 |
| Memantine Hcl | Memantine Hcl | 50 | 17 |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Fenofibrate | Fenofibrate | 48 | 14 |
| Spironolactone | Spironolactone | 48 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 48 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 46 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 13 |
| Ibuprofen | Ibuprofen | 44 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 44 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 42 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 17 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 42 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Valsartan | Valsartan | 39 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 11 |
| Lovastatin | Lovastatin | 38 | 13 |
| Methocarbamol | Methocarbamol | 38 | 14 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 37 | suppressed |
| Nystatin | Nystatin | 37 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | 21 |
| Gemtesa | Vibegron | 35 | 11 |
| Ondansetron Odt | Ondansetron | 35 | suppressed |
| Verapamil Er | Verapamil Hcl | 35 | suppressed |
| Prolia | Denosumab | 34 | 22 |
| Amoxicillin | Amoxicillin | 33 | 27 |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | 13 |
| Warfarin Sodium | Warfarin Sodium | 33 | 11 |
| Benazepril Hcl | Benazepril Hcl | 32 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 26 |
| Cephalexin | Cephalexin | 31 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 28 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 28 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Belsomra | Suvorexant | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 23 | suppressed |
| Testosterone | Testosterone | 23 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 22 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 22 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Mesalamine | Mesalamine | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 17 |
| Clobetasol Propionate | Clobetasol Propionate | 18 | 12 |
| Folic Acid | Folic Acid | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Almotriptan Malate | Almotriptan Malate | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Ergotamine-Caffeine | Ergotamine Tartrate/Caffeine | 13 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Tirosint | Levothyroxine Sodium | 13 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
| Serevent Diskus | Salmeterol Xinafoate | 11 | suppressed |
| Sulindac | Sulindac | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,285.39 · 128 records | GlaxoSmithKline, LLC. | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, Epclusa, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, KISUNLA, Kerendia, LEQVIO, LOREEV XR, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, Rybelsus, SHINGRIX, SPRAVATO, Senza, TRELEGY ELLIPTA, Tymlos, UBRELVY, UNITHROID, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error